The Promise and Limitations of Adjuvant Treatment in Liver Cancer with Prof Arndt Vogel

MedInsights Unleashed is an exciting new podcast aimed at providing valuable information and insights for patients and healthcare professionals.

In this first episode, hosts Zahra and John are joined by Professor Arndt Vogel to discuss key data from the adjuvant setting of liver cancer. They talk about the challenges of liver cancer treatment, the high mortality rate associated with the disease, and the progress made in recent years.

Professor Vogel provides an overview of the IMbrave 050 study, which was designed to investigate the efficacy of an adjuvant treatment combination of the checkpoint inhibitor atezolizumab and the targeted therapy bevacizumab in delaying or preventing recurrence compared with active surveillance. The study shows promising results in terms of improved recurrence-free survival, but longer follow up is needed to determine its impact on overall survival. The conversation also touches on the safety profile of the treatment and the importance of multidisciplinary teams in decision-making.